OOIR: Observatory of International Research

Papers

(The H4-Index of Acta Pharmaceutica Sinica B is 72. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods	1513
Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites	492
Why 90% of clinical drug development fails and how to improve it?	333
Gasdermin D in pyroptosis	264
Long non-coding RNAs: From disease code to drug role	241
Crystal structure of SARS-CoV-2 papain-like protease	198
The biology, function, and applications of exosomes in cancer	198
Metal-organic frameworks for advanced drug delivery	194
Probiotics modulate the microbiota–gut–brain axis and improve memory deficits in aged SAMP8 mice	191
Mitochondrial quality control mechanisms as molecular targets in cardiac ischemia–reperfusion injury	187
Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies	179
The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy	175
Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma	172
Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19	165
Recent progress of hypoxia-modulated multifunctional nanomedicines to enhance photodynamic therapy: opportunities, challenges, and future development	158
Ferroptosis is essential for diabetic cardiomyopathy and is prevented by sulforaphane via AMPK/NRF2 pathways	146
Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway	145
Targeting autophagy-related protein kinases for potential therapeutic purpose	138
Evolution of blood–brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies	133
Bioactive natural compounds against human coronaviruses: a review and perspective	131
Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity	127
Traditional Chinese medicine in COVID-19	126
Miltirone induces cell death in hepatocellular carcinoma cell through GSDME-dependent pyroptosis	123
New opportunities and challenges of natural products research: When target identification meets single-cell multiomics	121
Oral delivery of proteins and peptides: Challenges, status quo and future perspectives	119

Recent advances in drug delivery systems for targeting cancer stem cells	118
Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management	118
The progress and perspective of nanoparticle-enabled tumor metastasis treatment	116
Ginsenosides in Panax genus and their biosynthesis	115
Small interfering RNA for cancer treatment: overcoming hurdles in delivery	114
Antibody–drug conjugates: Recent advances in linker chemistry	113
Doxorubicin-loaded bacterial outer-membrane vesicles exert enhanced anti-tumor efficacy in non-small-cell lung cancer	112
Combating COVID-19 with integrated traditional Chinese and Western medicine in China	112
Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of in vivo studies	112
Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy	111
Pharmaceutical cocrystals: A review of preparations, physicochemical properties and applications	109
Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening	105
Synergetic delivery of triptolide and Ce6 with light-activatable liposomes for efficient hepatocellular carcinoma therapy	102
Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome	102
Current approaches of nanomedicines in the market and various stage of clinical translation	102
Recent advances of antibody drug conjugates for clinical applications	99
Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses	99
Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis	98
Extracellular vesicle activities regulating macrophage- and tissue-mediated injury and repair responses	96
Natural exosome-like nanovesicles from edible tea flowers suppress metastatic breast cancer via ROS generation and microbiota modulation	95
Advances and challenges in the treatment of esophageal cancer	94
Baicalin induces ferroptosis in bladder cancer cells by downregulating FTH1	93
Protective role of berberine on ulcerative colitis through modulating enteric glial cells–intestinal epithelial cells–immune cells interactions	93
Influencing factors and strategies of enhancing nanoparticles into tumors in vivo	93
The influence of the gut microbiota on the bioavailability of oral drugs	93
Analysis on herbal medicines utilized for treatment of COVID-19	93
In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges	93
Biological drug and drug delivery-mediated immunotherapy	92
Gene therapy for neurodegenerative disorders: advances, insights and prospects	91
Self-assembled natural phytochemicals for synergistically antibacterial application from the enlightenment of traditional Chinese medicine combination	90
Recent advances in drug delivery applications of cubosomes, hexosomes, and solid lipid nanoparticles	90
Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5	90
Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator	87
The cGAS–STING signaling in cardiovascular and metabolic diseases: Future novel target option for pharmacotherapy	85
Monoacylglycerol lipase inhibitors: modulators for lipid metabolism in cancer malignancy, neurological and metabolic disorders	82
Recent developments on PET radiotracers for TSPO and their applications in neuroimaging	81
Exploration and insights into the cellular internalization and intracellular fate of amphiphilic polymeric nanocarriers	81
Celastrol induces ferroptosis in activated HSCs to ameliorate hepatic fibrosis via targeting peroxiredoxins and HO-1	78
Recent development on COX-2 inhibitors as promising anti-inflammatory agents: The past 10 years	77
Nanomedicine-based drug delivery towards tumor biological and immunological microenvironment	77
Integrins as attractive targets for cancer therapeutics	77
Bone marrow mesenchymal stem cells-derived exosomes for penetrating and targeted chemotherapy of pancreatic cancer	77
Cell membrane-derived vesicles for delivery of therapeutic agents	76
Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years	76
Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy	75
Emerging role of natural products in cancer immunotherapy	73
An update on oral drug delivery via intestinal lymphatic transport	73
Ginsenoside Rg1 ameliorates blood–brain barrier disruption and traumatic brain injury via attenuating macrophages derived exosomes miR-21 release	72